CDC7 Inhibition Potentiates Antitumor Efficacy of PARP Inhibitor in Advanced Ovarian Cancer
CDC7 Inhibition Potentiates Antitumor Efficacy of PARP Inhibitor in Advanced Ovarian Cancer
About this item
Full title
Author / Creator
Liu, Shini , Deng, Peng , Yu, Zhaoliang , Hong, Jing Han , Gao, Jiuping , Huang, Yulin , Xiao, Rong , Yin, Jiaxin , Zeng, Xian , Sun, Yichen , Wang, Peili , Geng, Ruizi , Chan, Jason Yongsheng , Guan, Peiyong , Yu, Qiang , Teh, Bin‐Tean , Jiang, Qingping , Xia, Xiaojun , Xiong, Ying , Chen, Jianfeng , Huo, Yongliang and Tan, Jing
Publisher
Germany: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
Germany: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Poly (ADP‐ribose) Polymerase inhibitors (PARPi) have demonstrated remarkable clinical efficacy in treating ovarian cancer (OV) with BRCA1/2 mutations. However, drug resistance inevitably limits their clinical applications and there is an urgent need for improved therapeutic strategies to enhance the clinical utility of PARPi, such as Olaparib. Here...
Alternative Titles
Full title
CDC7 Inhibition Potentiates Antitumor Efficacy of PARP Inhibitor in Advanced Ovarian Cancer
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_a6bbf8a7716f41d0811c53e342b2b0f7
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_a6bbf8a7716f41d0811c53e342b2b0f7
Other Identifiers
ISSN
2198-3844
E-ISSN
2198-3844
DOI
10.1002/advs.202403782
